Our focus is developing highly-differentiated therapies against validated targets in oncology.
Our lead program is a best-in-class potential TROP2-targeted antibody drug conjugate (ADC), PBI-410.

PBI-410’s profile positions it as a potential best-in-class TROP-2 ADC, both as monotherapy and as the partner of choice for combination with anti-PD1.
PBI-410 is currently in IND-enabling studies, with a first-in-human trial anticipated to start in early 2024.

Trophoblast cell surface antigen 2 (TROP-2)

TROP-2 is a cell surface protein that is overexpressed in a wide variety of tumors.  TROP-2 is a validated target in oncology, with earlier generation TROP-2 ADCs showing clinical activity in patients with TROP2-expressing tumors.


PBI-410 (also known as GQ1010) is a next-generation, best-in-class potential TROP-2 ADC that preclinically has shown differentiation versus earlier generation TROP-2 ADCs.
The differentiated profile of PBI-410 is driven by the unique features of the bioconjugation platform technology developed by our partner GeneQuantum Healthcare (Suzhou) Co. Ltd., which renders PBI-410 as a fully optimized next-generation ADC construct using a novel linker-payload and enzymatic, site-specific conjugation.

A Highly Differentiated, Best-In-Class Profile

In in vivo preclinical TROP-2 expressing tumor models, PBI-410 has shown improved antitumor activity versus other TROP-2 ADCs. It also has demonstrated more potent in vitro cytotoxicity, superior bystander effect, and greater immunogenic cell death with the novel TopoIx payload as compared to other Topoisomerase 1-based payloads.

PBI-410 has also shown compelling in vivo synergistic growth inhibition in combination with anti-PD-1 therapy in a mouse syngeneic MC38 colon cancer model, superior to the activity observed with other TROP-2 ADC plus anti-PD1 combinations.

Preclinical safety findings of PBI-410 in non-human primates indicate a differentiated profile and potential for a wider therapeutic window vs other TROP-2 ADCs in development.